Our Leadership

Modus Therapeutics has a Board of Directors and Leadership Team with extensive experience of drug development, partnering and business in life science. This in combination with skilled external expertise, as consultants or advisors, creates a strong team with experience in taking pharmaceutical products to the market.

Board of Directors Leadership Team

Board of Directors

Björn Sjöstrand
Björn Sjöstrand
Chairman

Bjorn Sjöstrand has extensive experience gained from the vaccines industry in several international executive positions.

Torsten Goesch M.D Ph.D
Torsten Goesch M.D Ph.D
Board Member

Dr. Torsten Goesch has been the director of Rosetta Capital secondary life science investor since 2002, where he is responsible for the management of several Rosetta Capital investments.

Tomas Odergren M.D, Ph.D
Tomas Odergren M.D, Ph.D
Board Member

Dr. Tomas Odergren is an M.D and a Ph.D with a specialist interest in neurology. Dr. Odergren currently holds the position as Chief Expert at H Lundbeck A/S in Denmark.

Mats Wahlgren
Mats Wahlgren
Board Member

Professor Mats Wahlgren investigates the molecular pathogenesis of parasitic diseases. Previous positions include directorship of MTC (KI), the Multilateral Initiative on Malaria and the Infection and Vaccinology Programme (SSF).

Viktor Drvota M.D, Ph.D
Viktor Drvota M.D, Ph.D
Board Member

Viktor Drvota is Chief Investment Officer at Karolinska Development. He has more than 13 years of Venture Capital experience with several investments, significant fundraisings, IPOs and exits.

Leadership Team

Christina Herder Ph.D
Christina Herder Ph.D
Chief Executive Officer

Appointed in 2014. Christina Herder has more than 20 years of experience in drugs development and corporate development from the biotech and pharmaceutical industry.

Lena Jendeberg Ph.D
Lena Jendeberg Ph.D
Vice President, Development

Joining Modus Therapeutics in 2016, Lena Jendeberg has more than 20 years of experience in research and drug development in biotech and pharma.

Maria Lindgren Ph.D
Maria Lindgren Ph.D
Project Leader

Employed in 2010, Maria Lindgren has 15 years’ of experience in small biotech drug development companies, with project deliveries ranging from preclinical phase to phase II clinical trials.

Anna Leitgeb Ph.D
Anna Leitgeb Ph.D
Project Leader

Employed in 2005, Anna Leitgeb is one of the inventors of sevuparin and its use in treating VOC in sickle-cell disease and in malaria.